Amivantamab (Rybrevant) — targeted antibody for selected EGFR-driven lung cancer

What amivantamab is in simple patient language

Rybrevant is the brand name. Amivantamab is the drug name. It is not a pill. It is not regular chemotherapy. It is an antibody. The medicine goes into a vein.

The first line to check is the EGFR result in the lung cancer report. Often the question is an exon 20 insertion. Sometimes the question comes later, after earlier EGFR tablets have stopped holding the disease.

The word EGFR alone is not enough. The doctor needs the exact mutation, the scans, the earlier treatment history, breathing symptoms, skin and eye complaints, blood work, and the patient’s general strength. The first infusions also need planning, because reactions can happen during the drip.

How amivantamab works

Some lung cancer cells use surface signals to keep growing. EGFR is one of those signals. MET can also matter in the same story. This antibody is made to sit on EGFR and on MET.

One infusion is not expected to make everything vanish. In some patients, spots shrink. In others, the useful sign is slower movement of the disease. The doctor reads scans, cough, breathing, pain, blood tests, and side effects together.

The first part of treatment is also about safety. The body may react while the drug is going in. That is why early infusions are watched more closely than a routine tablet prescription.

Which diseases amivantamab may be used for

This drug is not a general lung cancer drug. It needs an EGFR reason and a clinical situation where that reason matters.

• NSCLC when the report points to an insertion in EGFR exon 20;
• lung cancer that has spread and needs treatment through the whole body;
• disease that moved again after earlier EGFR-directed treatment, if the new plan fits this antibody;
• cases where Rybrevant is compared with chemotherapy, another targeted drug, or a clinical trial;
• second opinion when the patient was told about Rybrevant but the reason is not clear.

Same mutation, different patient, different plan. Line of treatment, symptoms, pace on scans, lung condition, skin problems, and past reactions all change the answer.

When amivantamab can be especially relevant

It can become a serious option when the usual EGFR route is no longer enough, or when the mutation itself points away from standard tablet logic.

• an EGFR exon 20 insertion is written in the molecular report;
• the disease has spread and local treatment alone is not enough;
• previous treatment stopped keeping the cancer under control;
• the doctor is considering a plan that includes chemotherapy or another targeted medicine;
• fresh scans are needed to understand the true spread of disease;
• the family wants a second opinion before the next line of treatment starts.

The question is not whether the drug is strong. The question is what job it has now: slow the disease, shrink active spots, work after another drug, or help build the next step without too much extra risk.

What needs to be checked before starting

One old discharge letter is not enough. The doctor needs a current picture of the disease and the patient.

• tumor type and biopsy result;
• the EGFR test, with the exact change written clearly;
• recent CT, PET-CT, or brain MRI when needed;
• all previous cancer medicines and why they were stopped;
• CBC and blood chemistry;
• liver and kidney values;
• cough, breathlessness, chest pain, fever, or oxygen problems;
• skin, nail, mouth, and eye symptoms;
• regular medicines, including those taken only from time to time.

The infusion risk also gets discussed before the first day. The patient should know how the first drip is organized, why it may take longer, and what to say right away if something feels wrong.

How treatment with amivantamab goes

Amivantamab is given in the oncology unit. The patient does not start it alone at home. The first infusions are usually the most careful part of the plan.

During the drip, the team watches breathing, pressure, skin, chest comfort, weakness, and overall feeling. If a reaction appears, the infusion may slow down or stop for a while. Support medicine can be given. That does not always mean the drug is lost as an option.

What gets followed during treatment:

• how the person does during the drip and after it;
• skin rash, itch, dry patches, sore nails, cracks, redness;
• cough, new trouble breathing, pressure or pain in the chest;
• CBC and blood chemistry;
• liver and kidney values;
• swelling, appetite, body weight, tired days;
• sore or red eyes, eye pain, change in vision;
• planned scans to see what the disease is doing.

One bad reaction does not always close the door on the drug. The team can slow the drip, change the medicines given before it, pause Rybrevant, treat the skin, or bring lung checks forward. No one should guess this out at home.

Possible side effects

Different patients notice different problems. With this drug, the main areas are the infusion itself, skin and nails, lungs, eyes, stomach, swelling, and blood tests.

• reaction during infusion: heat, chills, breathing trouble, weakness, chest pressure;
• rash, dry skin, itching, painful skin;
• nail fold inflammation, cracks, sore fingers;
• mouth soreness or small ulcers;
• nausea, constipation, loose stool;
• swelling, tiredness, lower appetite;
• cough or new breathing trouble;
• eye irritation, pain, redness, or blurred vision;
• changes in blood tests or chemistry results.

Small symptoms are still useful information. Early skin care, eye advice, fluids, or a treatment pause can sometimes prevent a small problem from becoming a larger one.

When to contact the doctor without waiting

Do not wait for the next visit if any of these appear:

• trouble breathing, strong weakness, or chest pressure during infusion;
• swelling of the face, lips, tongue, or throat;
• rash spreading fast, blisters, painful skin, or fever with rash;
• new or worse shortness of breath;
• cough with fever or chest pain;
• eye pain, strong redness, or sudden vision change;
• repeated vomiting or heavy diarrhea;
• fainting, strong swelling, or a sharp drop in general condition.

The patient does not need to decide whether Rybrevant caused it. The safer move is to report it and let the medical team sort it out.

Why amivantamab is not right for everyone

Rybrevant can be important, but it does not fit every lung cancer case. Sometimes the EGFR change is not the one that supports this drug. Sometimes the body is not ready for the treatment burden.

• no suitable EGFR change is confirmed;
• previous therapy and new scans point to another route;
• active lung problems need to be clarified first;
• skin, nails, eyes, or mucosa are already in poor condition;
• high concern for a severe infusion reaction;
• general condition is too weak for the planned schedule;
• another treatment fits the current goal more cleanly.

Choosing another drug is not the same as rejecting modern treatment. It may simply fit the patient, the mutation, and the timing better.

Can amivantamab be combined with other treatments

Sometimes yes. The drug can stand alone in one plan and be part of a wider regimen in another. More drugs do not automatically mean a better plan.

• with chemotherapy in selected schedules;
• with another targeted drug when the oncologist has a clear reason;
• after previous EGFR therapy, if the new disease picture supports it;
• with radiation for a separate painful or risky spot;
• with support for rash, nails, mouth, stomach, eyes, or infusion reactions.

The useful question is simple: what is each part supposed to do, and how will side effects be watched? If that answer is vague, the plan needs another discussion.

What no quick response to treatment can mean

A response is not always clear after the first few weeks. The patient may already be receiving infusions while the first scan is still too early to answer much.

Sometimes the spots shrink. Sometimes the better news is quieter disease: less cough, steadier breathing, fewer new symptoms, slower change on scans. That can still matter, especially when the cancer was moving fast before.

One scan without comparison rarely tells the whole story. The doctor looks at images, symptoms, blood tests, side effects, and the pace before treatment. Then the plan can be continued, paused, or changed with a reason.

Oncology consultation in Israel about amivantamab

At Tel Aviv Medical Clinic, patients with EGFR-driven lung cancer can review whether amivantamab has a reasonable place in their case. This can help when Rybrevant was proposed, but the patient still needs to understand the mutation, previous therapy, infusion risk, and other options.

A consultation may help to:

• review the EGFR report and the exact mutation;
• understand why Rybrevant is being discussed now;
• compare this antibody with tablets, chemotherapy, or a trial;
• talk through infusion reactions, rash, lung symptoms, eye symptoms, and nail problems;
• prepare questions for the treating oncologist;
• organize the medical documents before the next decision.

We do not prescribe remotely and do not replace the treating doctor. We help the patient and family understand the logic of the plan and come to the next appointment prepared.

Frequently asked questions — answered by Dr. Stefanska

1. How is amivantamab different from EGFR tablets?

Most EGFR pills are taken at home. Rybrevant is not like that. It goes through a vein. The first visits are watched closely because the body can react during the drip.

Convenience is not how I choose here. I need the EGFR report, the old drugs, the dates, and the new scans. Then the question becomes clear: does this antibody have a job now?

2. Why is the EGFR test so important here?

The test tells us whether there is a reason to talk about this drug. Lung cancer alone is too broad. The small detail in the EGFR result matters.

I look at the actual report, not just a note in the discharge letter. Tissue or blood test, date, method, and whether the disease changed after treatment — all of that can matter. An old result can be useful. Sometimes it is not enough.

3. What if the patient feels bad during the first infusion?

Tell the nurse right away. Do not wait and see. Chills, heat, chest pressure, tight breathing, dizziness, weakness, or sudden flushing during the drip need to be seen at that moment.

Usually the team has steps ready: slow the drip, pause it, check oxygen and pressure, give support. The main thing is simple. The patient should not sit there quietly trying to be brave.

4. Does a rash mean the drug must be stopped?

No, not automatically. A mild rash is one story. Painful skin, cracks near the nails, blisters, fever, or a rash that spreads fast is another.

I want to hear about it early. Skin problems are easier to calm down at the start. If the patient waits until sleep, walking, or washing becomes painful, the plan gets harder to keep.

5. Which symptoms should not wait?

Breathing changes. Chest pain. Swelling of the lips, face, or throat. Fainting. Eye pain or a sudden change in vision. Rash with blisters. Severe diarrhea. Repeated vomiting. A sharp drop in strength.

These are not symptoms for the next routine visit. Maybe the drug is not the cause. Still, with this treatment I would rather check once too early.

6. Can Rybrevant be used after other EGFR treatment?

Sometimes yes. But that sentence by itself says almost nothing. Which EGFR pill? How long did it work? What did the last scan show? Was a new test done? Those answers change the plan.

I would also look at the patient’s lungs, skin, blood tests, and general strength. The next step should follow the disease story, not the wish to try another drug.

7. What documents are needed for a consultation?

Bring the papers that show the real timeline. Biopsy. EGFR report. Recent CT or PET-CT. Brain MRI if there is one. List of all previous drugs with dates. Blood tests. Notes about bad reactions.

I also like a short written story: diagnosis, first treatment, response, when the disease moved again, and what is being offered now. That saves time and makes the consultation more useful.

Important information

This page gives general medical information. It is not a prescription and not a personal treatment plan. Amivantamab is discussed only after the diagnosis, molecular report, scans, previous treatment, symptoms, and general condition are reviewed.

Do not start, stop, or change treatment without speaking with the treating physician.

Contacts

To arrange a consultation about amivantamab:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108